A federal appeals court in Washington denied Amgen Inc.â€™s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S.

The decision by the U.S. Court of Appeals for the Federal Circuit could clear the way for Novartis to begin selling Zarxio, a knockoff version of Neupogen that was approved by the U.S. Food and Drug Administration in March. The U.S. market...